• 1
    Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharm Ther 1995; 58: 4927.
  • 2
    Lown KS, Mayo RR, Leichtman AB, Hsaio H, Turgeon K, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharm Ther 1997; 62: 24860.
  • 3
    Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, Von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 14753.
  • 4
    Robin DW, Lee M, Hasan SS, Wood AJ. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 6307.
  • 5
    Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism by the gut. Lancet 1991; 338: 144890.
  • 6
    Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 1424.
  • 7
    Gonzales FJ. Molecular genetics of the P-450 superfamily. Pharmac Ther 1990; 45: 138.
  • 8
    Nebert DW, Russel DW. Clinical importance of the cytochromes P450. Lancet 2002; 360: 115562.
  • 9
    Wrighton SA, Vandenbranden M, Ring BJ. The human drug metabolising cytochromes P450. J Pharmacokin Biopharm 1996; 24: 46173.
  • 10
    Ueda K, Cornwell MM, Pastan I, Roninson IB, Ling V, Riordan JR. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141: 95662.
  • 11
    Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 1986; 46: 59416.
  • 12
    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 77358.
  • 13
    Schwab M, Schaeffler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger U, Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 2633.
  • 14
    Panwala C, Jones J, Viney J. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdrla, spontaneously develop colitis. J Imunnol 1998; 161: 573344.
  • 15
    Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 16993.
  • 16
    Finnström N, Thörn M, Lööf L, Rane A. Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 2001; 57: 4039.
  • 17
    Thörn M, Lundgren S, Herlenius G, Ericzon B-G, Lööf L, Rane A. Gene expression of cytochrome P450 in liver transplants over time. Eur J Clin Pharmacol 2004; 60: 41320.
  • 18
    Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, Brown AM. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Disp 2000; 28: 7818.
  • 19
    Klotz U, Hoensch H, Schütz T, Beaune P, Zanger U, Bode JC, Fritz P. Expression of intestinal drug-metabolising enzymes in patients with chronic inflammatory bowel disease. Curr Therapeut Res 1998; 59: 55663.
  • 20
    George J, Liddle C, Murray M, Byth K, Farrell GC. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995; 49: 87381.
  • 21
    Sumida A, Kinoshita K, Fukada T, Matsuda H, Yamamoto I, Inaba T, Azuma J. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun 1999; 262: 499503.
  • 22
    Rodrigez-Antona C, Donato MT, Pareja E, Gómez-Léchon M-J, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001; 393: 30815.
  • 23
    Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of a glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 102936.
  • 24
    Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificity and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcin 1995; 13: 12934.
  • 25
    McKinnon RA, Burgess WM, De La Hall PM, Roberts-Thompson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastro-intestinal tissues. Gut 1995; 36: 25967.
  • 26
    Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 24759.
  • 27
    Hebert MF. Contributions of hepatic and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 2014.
  • 28
    Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 155262.
  • 29
    Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27: 8049.
  • 30
    Kivistö KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 3879.
  • 31
    Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeniety in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 94755.
  • 32
    Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grape-fruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 254553.
  • 33
    Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27: 38391.
  • 34
    Thummel KE. Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 2003; 13: 5857.
  • 35
    Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595606.
  • 36
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 2659.
  • 37
    Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 15959.
  • 38
    Stephens RH, Tanianis-Hughes J, Higg NB, Humphrey M, Warhurst G. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdra (-/-) mouse intestine. J Pharmacol Exp Ther 2002; 303: 1095101.